Canadian pharmaceutical company Lexaria Bioscience Corp (LEXX) fell 27.4% in early trading after the company announced the termination of its $5 million stock sales agreement with JonesTrading. This decision reflects the company's strategic adjustment to optimize its capital structure and market positioning.